Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.84 USD
-0.03 (-1.60%)
Updated May 23, 2024 04:00 PM ET
After-Market: $1.84 0.00 (0.00%) 6:28 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 41 - 60 ( 313 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Hitting Real Strides With Cash Flow and Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Reports Full Year 2021 Results With $68.8M in Revenues- 30 Trials 7 Pivotal
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Avenue Therapeutics (ATXI-Not Rated): FDA Advisory Panel Says No.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Major Partner Company Positive News As of Late While Giving Up the Tramadol Ghost; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Help Even Closer for Menkes Patients As Well As Meaningful Cash Flow to Fortress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Recap - Building Positive Momentum; PT to $6
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Pivotal Times for Fortress and Partner Companies; Busier Than Ever
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
CUTX-101 Shows Further Promising Clinical Benefit in Menkes Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Caelums Acquisition Is Set to Pay Outstanding Return; Fortress Business Model Validation Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: $64M payable to Fortress- AstraZenecas Alexion
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Recap - Catalysts Could Turn Momentum Positive
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S